^
    Back
    Association details:
    Biomarker:FH mutation
    Cancer:Renal Cell Carcinoma
    Drug Class:Immunotherapy +
    Tyrosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur Urol
    Title:

    Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma

    Published date:
    06/15/2022
    Excerpt:
    A total of 77 patients were identified, including 70 cases with a germline FH alteration...Sixty-seven patients were evaluable for response to first-line systemic therapy with Bev/Erlo (n = 12), TKI monotherapy (n = 29), or ICI/TKI (n = 26). ICI/TKI combination therapy was associated with more favorable overall survival on systemic treatment (hazard ratio [HR] 0.19, 95% confidence interval [CI] 0.04–0.90) and progression-free survival on first-line therapy (HR 0.22, 95% CI 0.07–0.71) compared to Bev/Erlo combination therapy.
    DOI:
    https://doi.org/10.1016/j.eururo.2022.05.029